Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery

NCT00242502 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Liver Cancer

Interventions

DRUG: Bevacizumab (Avastin)
DRUG: Erlotinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]